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Abstract 
The incidence of type 1 diabetes (T1D) has been increasing among children and adolescents, 
which environmental factors including gut microbiota play an important role. However, the 
underlying mechanisms are yet to be determined. Here, we show that patients with newly 
diagnosed T1D displayed not only a distinct profile of gut microbiota associated with decreased 
short-chain fatty acid (SCFAs) production, but also an altered IgA-mediated immunity compared 
with healthy control subjects. Using germ-free (GF) non-obese diabetic (NOD) mice, we 
demonstrate that gut microbiota from patients with T1D promoted different IgA-mediated 
immune responses compared with healthy control gut microbiota. Treatment with the SCFA, 
acetate, reduced gut bacteria-induced IgA response accompanied by decreased severity of 
insulitis in NOD mice. Our study provides new insights into the functional effects of gut 
microbiota on inducing IgA immune response in T1D, suggesting that SCFAs might be potential 
therapeutic agents in T1D prevention and/or treatment. 
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Introduction 
Type 1 diabetes (T1D) is an immune-mediated disease resulting from the destruction of insulin-
producing pancreatic β cells. Recent evidence suggests the incidence of T1D has been increasing 
at a rate of up to 4% per year among children and adolescents (1). This increase in incidence is 
not attributed to genetics alone, as concordance for T1D between twins T1D is < 50% and newly 
onset T1D individuals exhibit fewer high-risk HLA-haplotypes (2-4). Thus, changes in the 
environment including the gut microbiota have been suggested to modulate the susceptibility to 
T1D. Studies in both non-obese diabetic (NOD) mice and humans have identified microbial 
composition changes between those that develop T1D and those that do not (5-9). In addition, in 
humans, altered gut microbial composition in early life and microbial immunogenicity have been 
linked with islet β cell autoimmunity (10, 11). Moreover, it has been shown in both NOD mouse 
model and T1D patients that bacterial mimics of pancreatic autoantigens can be recognized by 
autoreactive T cells(12-14). Understanding the functional interactions between the gut 
microbiota and the immune system in T1D beyond the composition is therefore important. 
 
Short-chain fatty acids (SCFAs) are microbial metabolites produced from the fermentation of 
dietary material by the intestinal microbiota, and the changes in microbiota composition can 
influence the production of SCFAs. SCFAs such as acetate, butyrate and propionate have been 
shown to induce regulatory T cells (Tregs) and B cell antibody production (15, 16). Interestingly, 
NOD mice given highly butyrated or acetylated diets were protected from T1D development due 
to increased frequencies of Tregs and reduced frequencies of autoreactive T cells (17). 
Furthermore, several bacterial pathways contributing to the synthesis of SCFAs are more 
prominent in healthy controls than in individuals with T1D (18). In addition, patients with T1D 
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have reduced levels of circulating SCFAs compared to healthy controls (19). Thus, changes in 
SCFAs levels have profound impacts on host immunity, in this case, islet β cell autoimmunity. 
 
IgA maintains gut homeostasis with ~40mg/kg of IgA produced each day in the human intestine 
(20). Microbes and/or endoplasmic reticulum (ER) stress in intestinal epithelial cells can induce 
IgA immune responses (21, 22). In most cases, IgA induced is polyreactive and can bind to many 
different types of bacteria (23). Interestingly, bacteria bound by IgA are more colitogenic than 
non-IgA-bound bacteria in inducing colitis (24). To this end, a recent study showed that serum 
IgA from individuals with T1D have a differential ability to bind specific bacteria compared to 
that from healthy controls (25). Furthermore, IL-10 production from recirculating intestinal IgA+ 
B cells protected mice from developing autoimmune encephalomyelitis (26). Thus, both IgA+ B 
cells and secreted IgA have important roles in mediating gut homeostasis and the susceptibility 
to autoimmunity. However, the IgA immune response to the altered gut microbiota and their 
SCFA production from individuals with T1D has not previously been established. 
 
In this study, we investigated the stool microbial composition and SCFAs productions from 
pediatric donors with T1D and age- and gender-matched healthy controls to determine what 
functional impact the gut microbiota from these two groups has on the IgA immunity. Utilizing 
germ-free (GF) NOD mice and specific pathogen-free (SPF) NOD mice, we found that microbial 
SCFAs, particularly acetate, modulated the IgA immune response and suppressed the generation 
of germinal center B cells. Most importantly, acetate reduced the infiltration of CD4+ T cells in 
the islets and ameliorated the progression of insulitis, indicating that SCFAs might be potential 
therapeutic agents in T1D protection and/or treatment. 
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Results  
Altered composition of gut microbiota is associated with decreased SCFA production and 
increased IgA-binding in T1D patients 
To explore the cross-talk of gut microbiota, SCFAs and IgA immune responses in T1D, we first 
studied the stool microbiota composition from newly-diagnosed pediatric donors (the average 
duration of diabetes was 5 months and the range was 3 days to 12 months), and age- and gender-
matched healthy control subjects (Table 1 and Figure 1A). Of the 19 patients, 18 were positive 
for one or more of the three autoantibodies to glutamic acid decarboxylase (GAD), insulinoma 
associated protein 2 (IA2), and zinc transporter 8 (ZnT8). None of the healthy controls was 
positive for any of the islet autoantibodies. We found increased α-diversity (Figure 1B and 1C), 
with a significant increase in the relative abundances of Ruminococcaceae and Coprococcus 
(Firmicutes) at the species level in individuals with T1D, compared to control subjects (Figure 
1D-E). In contrast, there was a significant reduction in the relative abundances of Roseburia and 
Megamonas (Firmicutes) at the species level (Figure 1F-G). To determine whether the stool 
microbial composition changes influenced the microbial production of SCFAs, we measured 
stool microbe-derived SCFAs by gas chromatographic mass spectrometer (GC-MS). We found 
significant reductions in acetate, butyrate and propionate concentrations in individuals with T1D 
compared to age- and gender-matched healthy controls (Figure 1H-I and Figure S1A), while the 
levels of hexanoic acid, isobutyrate, valerate and isovalerate were unchanged (Figure S1B-E). 
Interestingly, acetate was positively correlated with β cell function, as indicated by the level of 
fasting C peptide (FCP) (Figure 1J). It was reported that secretory IgA has the capacity to bind 
bacteria and regulate the composition and function of gut microbiota (23). More recently, 
differences in IgA binding to bacteria have been linked to both inflammatory bowel disease and 
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T1D (24, 25). Thus, we investigated the proportion of IgA-bound bacteria in our study subjects. 
We detected a higher proportion of IgA-bound bacteria in individuals with T1D compared to 
healthy control subjects (Figure 2A-B). Furthermore, the level of these IgA-bound bacteria was 
negatively correlated with the concentration of stool SCFAs, including acetate, butyrate and 
propionate (Figure 2C-E) and thus we observed a higher proportion of IgA-bound gut bacteria 
and lower concentrations of three SCFAs. Moreover, serum IgA and stool acetate, but not 
butyrate or propionate, were negatively correlated in T1D patients (Figure S2A-C). In addition, 
stool acetate concentration was negatively associated with the abundance of Eubacterium and 
Hathewayi (Firmicutes), and stool butyrate concentration was negatively correlated to 
Enterococcaceae (Firmicutes) level (Figure 2F-H). Taken together, our data support the 
hypothesis that newly-diagnosed individuals with T1D have altered gut microbiota, resulting in 
reduced concentrations of SCFAs. Interestingly, the altered gut microbiota promoted an 
increased IgA response to the bacterial targets, hence there were more IgA-bound gut bacteria in 
patients with T1D. These results suggest that SCFA may regulate bacteria-reactive IgA immune 
responses. 
 
Stool microbiota from individuals with T1D enhance intestinal permeability and alter immune 
cell function 
To directly test the function of the gut microbiota from patients with T1D to stimulate host 
immune responses in vivo, we orally gavaged GF NOD mice with stool microbiota from four 
randomly selected T1D patients and their matched healthy controls (Table S1 and Figure 3A). 
We demonstrated that gut bacterial composition of the mice receiving fecal bacteria from 
individuals with T1D showed clear separation by donor (Figure 3B). This contrasted with that 
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from the mice receiving fecal bacteria from control donors, in which the gut bacterial 
composition clustered together (blue circles in Figure 3B). Our results also revealed significant 
differences at the species level between the two groups (Figure 3C). To determine bacterial 
effects on the gut barrier in vivo, we assessed gut permeability and intestinal antimicrobial 
peptide expression. Mice receiving fecal bacteria from T1D donors exhibited increased gut 
permeability in vivo (Figure 3D). Of seven intestinal antimicrobial peptide genes tested, 
cathelicidin-related antimicrobial peptide (Cramp) was down-regulated in the mice receiving 
fecal bacteria from the patients (Figure 3E and Figure S3A-F). This suggests that altered 
bacterial composition from the donors with T1D predominantly changed gut permeability and 
more selectively altered the antimicrobial peptide responses in the intestine. Given that we found 
significantly altered IgA immune response to the fecal bacteria in individuals with T1D (Figure 
2B), we next assessed IgA immunity in GF NOD mice colonized with these bacteria. Compared 
to the controls, we found that mice receiving fecal bacteria from individuals with T1D had 
decreased percentages of IgA+ B cells in the pancreas-draining lymph nodes (PLN) (Figure 3F), 
and increased proportions of IgA-bound bacteria in the cecum, colon and stool (Figure 3G-H), 
the latter of which are consistent with our human data (Figure 2B). Furthermore, we found 
reduced free IgA antibodies in the colon and stool of the mice colonized with fecal bacteria from 
patients with T1D compared to the control subjects (Figure S4A). Interestingly, the GF recipients 
colonized with fecal bacteria from patients with T1D had increased frequencies of transitional B 
cells (CD21-CD23+) and reduced frequencies of marginal zone B cells (CD21+CD23-) in PLN 
and mesenteric lymph nodes (MLN) (Figure S4B-C). The bacteria from patients with T1D were 
also less able to induce Tregs in the large intestinal lamina propria compared to the bacteria from 
control subjects (Figure S4D). In addition, we identified increased frequencies of CD4+IFNγ+ 
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and CD8+TNFα+ T cells in the mice colonized with fecal bacteria from patients with T1D, 
compared with mice received bacteria from control donors (Figure S4E-F). To determine 
whether the immune cell function was affected by exposing to gut bacteria from patients with 
T1D, we stimulated the splenocytes from GF mice colonized with gut bacteria from either 
patients with T1D or healthy control subjects with anti-CD40 or anti-CD3 monoclonal antibody 
(mAb). We found that the GF recipients colonized with the bacteria from patients with T1D had 
increased proliferative responses of immune cells to anti-CD40 and anti-CD3 stimulation 
compared to GF recipients colonized with bacteria from healthy control subjects (Figure S5A-B). 
We also stimulated the splenocytes with microbial products - lipopolysaccharides (LPS), CpG 
and Pam3Csk (Figure S5C-E). Interestingly, there were no significant differences when 
splenocytes were stimulated with LPS or CpG; however, Pam3Csk stimulation induced higher 
proliferative responses in splenocytes from GF recipients colonized with gut bacteria from 
patients with T1D compared to that from the recipients received bacteria healthy control subjects 
(Figure S5C-E). Taken together, our results suggest that gut bacteria from individuals with T1D 
promote a “leaky” gut, alter B cell IgA immune responses and induce proinflammatory T cell 
responses. 
 
SCFAs modulate gut microbiota-mediated IgA immune response 
SCFAs are important for maintaining the intestinal barrier and promoting immune homeostasis 
(16). We have demonstrated, when tested directly ex vivo, that individuals with T1D had altered 
IgA immune responses compared to healthy control subjects, similar results were also found in 
GF mice when colonized with the gut bacteria from patients with T1D. Therefore, we 
hypothesized that the altered IgA response was mediated through the changes in microbially-
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derived SCFAs. To determine the relationship of the IgA response with SCFAs in T1D, we 
cultured the splenocytes from SPF NOD mice with SCFAs (acetate, butyrate or propionate), in 
the presence of LPS and anti-CD40 mAb. Interestingly, all tested SCFAs inhibited the IgA 
production (Figure 4A). Given the negative correlation between the acetate concentration in stool 
samples and the serum IgA level in patients with T1D (Figure S2A), we focused on investigating 
the effect of acetate on IgA immune responses in vivo. To this end, we colonized GF NOD mice 
with stool bacteria from T1D donors and followed by gavaging the mice with either acetate or 
sterile water (H2O, solvent for acetate) (Figure 4B). It is intriguing that acetate treatment for only 
one week significantly altered the α-diversity of gut microbiota (indicated by Chao richness, 
Figure 4C), and the relative abundance of Porphyromonadaceae (Bacteroidetes), as well as 
Staphylococcus (Firmicutes), at the family level in the stools of the ex-GF NOD mice (Figure 
4D-E). In addition, acetate decreased CD8+ T cell proportion in the Peyer’s patches (PP) (Figure 
4F) and increased the proportion of Tregs (Figure 4G). IgA+ B cells were significantly reduced in 
the PLN (Figure 4H). IgA+ B cells as well IgM+ B cells were also reduced in the bone marrow in 
acetate-treated mice (Figure 4I). Moreover, free IgA content in the cecum was reduced in when 
mice were treated with acetate (Figure 4J). These data suggest that microbial metabolites SCFA 
regulate IgA immune responses in NOD mice. 
 
Long-term treatment with acetate reduces IgA binding to bacteria, inhibits germinal center B 
cell formation and ameliorates insulitis 
To investigate the long-term effects of acetate on modulating IgA immune responses and β cell 
autoimmunity prior to T1D development in vivo in a conventional setting, we treated SPF NOD 
mice with acetate for 10-12 weeks (Figure 5A). Acetate treatment led to consistent reduction of 
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IgA-bound gut bacteria (Figure 5B) and improved intestinal barrier function, indicated by 
decreased gut permeability (Figure 5C). Similar to the short-term acetate treatment of ex-GF 
mice (Figure 4J), long-term treatment of SPF mice also decreased IgA content in the cecal lumen 
(Figure 5D) and reduced the proportion of IgA-bound bacteria in the small intestine (Figure 5E), 
which coincided with lower expression of polymeric Ig receptor (Pigr) (Figure 5F). To assess 
the IgA binding ability to microbes, we studied the bacterial binding ability of IgA, in the 
intestinal washing or serum from acetate-treated and control mice, to gut bacteria from Rag-
deficient NOD mice (devoid of antibodies). Acetate treatment reduced intestinal IgA binding to 
gut bacteria (Figure 5G), but not serum IgA binding to gut microbiota (Data not shown). Acetate 
administration also reduced both CD19+ B cells and CD4+ T cells in the PP (Figure 5H), while 
the proportion of IgA+ B cells was only reduced in the spleen (Figure 5I). However, we observed 
decreased germinal center (GC)-B cells (PNA+GL7+) in the MLN and PP of acetate-treated mice 
(Figure 6A), together with reduced IgA+ GC-B cells in the spleen of mice that received long-
term acetate treatment (Figure 6B). We also found reduced IgA+ B cells in the bone marrow 
(Figure 6C), which is in line with short-term acetate treatment in ex-GF NOD mice (Figure 4I). 
Long-term acetate treatment also reduced IgD+ B cells in the bone marrow (Figure 6C). 
Importantly, acetate-treated mice displayed ameliorated insulitis, in contrast to the controls 
(Figure 6D-E), accompanied by reduced CD4+ T cell infiltration in the islets (Figure 6F). Our 
data suggest that acetate reduces IgA immune responses to bacteria and ameliorates β cell 
autoimmunity. 
 
Finally, to investigate the direct effect of acetate on IgA immune responses, we stimulated the 
purified splenic B cells from acetate-treated or control mice with LPS and anti-CD40 mAb, in 
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the presence of acetate. We found that B cells from acetate-treated mice secreted significantly 
less IgA compared with that from control mice in vitro (Figure 7A). IL-6, essential for B cell 
differentiation, maturation and survival (27, 28), was reduced at cellular level (Figure 7B-C) and 
secreted molecular level (Figure 7D) when acetate was present. qPCR analysis of purified 
splenic B cells from acetate-treated mice demonstrated reduced expression of post-switch 
transcripts-α (Pstα), Pst2β, signal transducer and activation of transcription 5b (Stat5b) and 
interferon regulatory factor 4 (Irf4) compared to that from control mice (Figure 7E-H), all of 
which are important for B cell differentiation. However, there were no significant differences in 
the expression of activation-induced cytidine deaminase (Aid), x-box binding protein 1 (Xbp1), 
paired box 5 (Pax5) and pr-domain zinc finger protein 1 (Prdm1) (Figure S6A-D). Although 
SCFAs were reported to induce intracellular signaling changes by activating the orphan 
metabolite-sensing G-Protein Receptor (GPR41) and GPR43 (29), we did not find any changes 
in Gpr41 or Gpr43 expression between acetate-treated and non-acetate-treated donor B cells 
(Figure 8A-B). However, a member (A7) of solute carrier family 16 (SLC16) transporting 
SCFAs (30) was significantly reduced on B cells from acetate-treated mice (Figure 8C), while 
the other members tested were not affected (Figure 8D-E). Taken together, our findings suggest 
that acetate treatment alters bacteria-targeting IgA immune responses, and affects B cells by 
reducing IL-6 production and GC-B cell generation, most likely mediated through SLC16A7 
pathway. 
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Discussion 
In this study, we report several novel findings: 1) newly diagnosed T1D patients show increased 
proportion of stool IgA-bound gut bacteria, which is negatively associated with the 
concentrations of some SCFAs, especially acetate; 2) the level of stool acetate is negatively 
associated with circulating IgA concentration; 3) colonization of germ-free NOD mice with stool 
bacteria from patients with T1D or healthy control subjects revealed distinct profiles of gut 
microbiota in the colonized germ-free NOD mice; 4) gut microbiota from patients with T1D 
enhanced gut permeability; 5) similar to the stool samples seen in the patients with T1D, germ-
free NOD mice colonized with stool bacteria from the patients also had higher proportions of 
IgA-bound gut bacteria but lower levels of “free” IgA in the intestine compared to mice 
colonized with gut bacteria from healthy control subjects; 6) acetate modulated B cell IgA 
responses in vitro and in vivo. Thus, our study provides a novel link between the IgA immune 
response and gut microbiota modulated by acetate, in the immuno-pathogenesis of T1D. 
 
B cells were documented to play different roles in the initiation and progression of T1D. Our 
previous studies and the studies by other scientists showed that B cell-deficient (μMT-/-) NOD, 
which are also deficient in immunoglobulin production, are protected against T1D development, 
indicating that B cells and the antibodies produced by B cells may facilitate the development of 
T1D (31-33). Among antibodies produced by B cells, IgA has been demonstrated to “coat” a 
substantial fraction of intestinal bacteria and is an important component of the gut homeostatic 
barrier together with mucus and antimicrobial peptides (34). In this study, we found that newly-
diagnosed patients with T1D had increased level of IgA-bound gut bacteria, in contrast to 
healthy control subjects. Colonizing GF NOD mice with gut bacteria from patients with T1D 
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changed the host IgA immune response including an increased ability of IgA to bind gut 
microbiota and decreased free gut luminal IgA. Zeng and colleagues showed that gut bacteria 
promote IgG antibody secretion in the host by releasing microbial products that act as antigens 
and ligands for B cell receptors (BCR) and Toll-like receptors (TLRs), respectively (35). Other 
studies reported that IgA production can be enhanced by TLR3 agonist poly I:C and TLR5 
agonist flagellin (36, 37). Further, microbial metabolite SCFAs can either promote or inhibit the 
production of IgA, depending on the concentration of SCFAs (16). The modulation of IgA 
production can be mediated by B cell metabolism and gene expression for plasma cell 
differentiation, as well as induction of the vitamin A-converting enzyme expression in intestinal 
epithelial cells (16, 38). In this study, we demonstrated that patients with T1D have significantly 
lower concentrations of stool SCFAs than matched healthy controls; moreover, the levels of 
SCFAs are associated with increased level of IgA-bound gut bacteria, suggesting that gut 
microbiota-derived SCFAs modulate the targeting ability of IgA to specific commensal bacteria 
in T1D.  
 
Recently, Marino and colleagues reported that feeding NOD mice with combined acetate- and 
butyrate-enriched diets led to T1D protection, by reduction of autoreactive T cells and expansion 
of regulatory T cells (17). The authors also found that gut microbiota such as Christensenella 
negatively correlated with fecal acetate in NOD mice (17). Interestingly, we found that GF NOD 
mice colonized with fecal bacteria from patients with T1D have a significantly lower abundance 
of Christensenella, compared to mice colonized with fecal bacteria from healthy control subjects. 
Moreover, by colonizing GF NOD mice with patients’ bacteria, followed by administration of 
acetate to the mice, we demonstrated that acetate modulated the IgA immune response induced 
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by gut bacteria from the patients with T1D. We also show that acetate ameliorated the self-
destruction of islet β cells by reducing CD4+ T cell infiltration in the islets and ameliorate the 
progression of insulitis in NOD mice. Supporting the findings by Marino and colleagues (17), we 
found that the long-term treatment with acetate in NOD mice induces Treg cell expansion, but 
only in Peyer’s patches. Further studies are required to probe the role of Treg cells in IgA 
immunity in T1D. However, our study revealed that acetate reduced the population of GC B cells 
in the gut-associated lymphoid tissues and inhibited the molecules essential for B cell 
differentiation. Although activation-induced cytidine deaminase (Aid), which is essential for IgA 
class switching (39) remained unchanged in B cells, Pst transcription factors such as Pstα and 
Pst2b, and Irf4 were inhibited in NOD mice that received acetate treatment. Class switching in B 
cells to the IgA isotype requires induction of transcription in the Cα switch region (Sα), which 
can be initiated by a number of factors including transforming growth factor-β1 (TGF-β1), IL-4, 
IL-6, IL-10 and retinoic acid (34). Our results showed that SCFA inhibited splenic IL-6 
expression in B cells, indicating that reduced IL-6 expression may contribute to the decreased 
IgA production. 
 
It is known that IgA+ B cells reside in different lymphoid and non-lymphoid tissues (23, 40-43). 
In this study, we found that acetate treatment inhibited the production of bone marrow IgA+ B 
cells in both colonized GF NOD mice and SPF NOD mice. In addition, acetate inhibits the 
population of GC B cells in the MLN and PP, which are considered as important primary sites 
for IgA immune response (40, 44). Polymeric Ig receptor (pIgR) is a transmembrane protein 
expressed on the surface of intestinal epithelial cells and regulates a key pathway for IgA 
secretion by acting as a transport receptor for IgA (45). After transportation, pIgR becomes a part 
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of the secreted IgA molecule and plays an important role in making the IgA molecule less 
susceptible to proteolytic digestion, thus increasing the capacity of the IgA molecule to target 
potential pathogens, thereby inhibiting their attachment to the epithelial surface (46, 47). Here 
we found that acetate suppressed the gene expression of Pigr in the gut and reduced the 
percentage of IgA-bound bacteria, as well as decreased the “coating” ability of the free IgA to 
gut microbiota. Thus, our results reveal that acetate modulates the IgA immune response to 
commensal bacteria, potentially by decreasing the expression of Pigr, leading to suppressed IgA 
immunity.  Further proof could be provided by testing genetically-modified NOD mice with Pigr 
deficiency and/or overexpression, which could be a future direction.  
 
Taken together, we demonstrate that gut bacteria from patients with T1D alter the host intestinal 
and systemic IgA immune responses, which are mediated by gut microbiota-derived SCFAs.  
The contribution of the host intestinal and systemic IgA immune responses, associated with gut 
microbiota, to directly causing T1D development in humans would be confirmed in a future 
longitudinal study in pre-diabetic individuals. However, our cross-sectional study provides novel 
insights regarding the function of gut microbiota and their metabolites in the immuno-
pathogenesis of T1D.  
 16 
Methods 
Human samples 
Human samples were collected from pediatric patients with T1D, diagnosed within one year of 
diagnosis, and gender- and age-matched healthy control subjects who were 6 to 18 years old at 
the time, in the Diabetes Center of the Second Xiangya Hospital of Central South University, 
China. Exclusion criteria included: 1) Active infection and/or antibiotic treatment, or any 
infection or antibiotic treatment within the 3 months prior to the sample collection; 2) Active or 
recent consumption of probiotics; 3) Any signs of acute or chronic inflammation; 4) Oral 
contraceptives or pregnancy; 5) Any medication, other than for diabetes management (insulin 
usage); 6) Individuals with a known history of immune dysfunction, such as allergy, asthma, 
other autoimmune diseases including systemic lupus erythematosus (SLE), Crohn’s disease, 
rheumatoid arthritis, and multiple sclerosis; 7) Individuals with a known history of malignancy 
or other diseases including gastrointestinal tract, liver and kidney disorders; 8) Individuals 
diagnosed with psychiatric disorders including any individuals prescribed psychiatric 
medications. T1D was diagnosed in accordance with the criteria of the American Diabetes 
Association (2018). Patients with T1D were selected randomly (with sufficient quantity of the 
study materials) and control subjects were age- and gender-matched. The study was conducted 
according to Declaration of Helsinki principles. 
 
Mice 
Mice used in this study were housed in strict germ-free (GF) or specific pathogen free (SPF) 
facilities with a 12-hour-dark/light cycle at Yale University. The GF non-obese diabetic (NOD) 
breeders were kindly provided by Dr. A Chervonsky (University of Chicago, Chicago). SPF 
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NOD mice and Rag-/- NOD mice were originally obtained from the Jackson Laboratory and 
maintained at Yale University. At least 6 or more mice per experiment were used for the purpose 
of reproducibility and statistical significance. Mice were randomly allocated in the different 
experimental groups from different cages, ensuring that mice of the same age and gender were 
taken from a mixed pool of different breeders. All data from mouse studies were representative 
of two or more independent experiments. 
 
Extraction of gut bacterial DNA 
Fresh human stool samples, collected using sterile procedure, were immediately aliquoted and 
frozen at -80°C before use. Stool samples from humans or mice were resuspended in TE buffer 
(10 mM Tris and 1 mM EDTA, pH = 8) containing 0.5% SDS and 200 μg/ml Proteinase K. After 
incubation at 37°C for 1 h, the samples were homogenized in solution containing 
phenol/chloroform/isoamyl alcohol, 20% SDS and zirconium silica beads. Following 
centrifugation (15 mins, 4°C, 12000 g), the upper aqueous layer containing DNA was removed 
and transferred to a new tube. Bacterial DNA was subsequently precipitated by isopropanol and 
washed with 70% ethanol. 
 
16S rRNA sequencing and data analysis 
Fresh samples were collected from both outpatients and inpatients using a sterile wooden spatula 
into a sterile container.  The collected stool samples were immediately aliquoted into small vials 
in the laboratory and frozen at -80 ºC within two hours from the time of sample collection. 
Bacterial 16S rRNA V4 region was amplified from each DNA sample by PCR using barcoded 
primer pairs (5’-GTGCCAGCMGCCGCGGTAA-3’) and (5’-GGACTACHVGGGTWTCT 
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AAT-3’). The PCR products were purified using a Qiagen gel extraction kit. After the 
quantification of DNA concentration with Nano-Drop II, samples were pooled for 
pyrosequencing using the Ion Torrent Personal Genome Machine (PGM) sequencing system 
(Life Technologies). The sequencing results were analyzed with the QIIME software package 
and UPARSE pipeline to pick operational taxonomic units (OTUs). α-diversity was measured by 
Observed species number, Phylogenetic diversity (PD) or Chao richness in the bacterial 
communities. β-diversity was calculated to compare differences between microbial communities, 
shown as Principal Coordinate Analysis (PCoA). Taxonomy assignment was performed at 
various levels using representative sequences of each OTU. The sequencing data have been 
deposited in the SRA database and the accession numbers are PRJNA615687 (T1D patient and 
healthy control stool samples), PRJNA615637 (Fecal samples of GF NOD mice colonized with 
human bacteria), and PRJNA615380 (Fecal samples of GF NOD mice colonized with T1D 
patient bacteria followed with acetate treatment). 
 
IgA-bound bacterial staining 
Human or mouse fecal samples were resuspended at 1 g/mL in sterile PBS and homogenized by 
vortexing vigorously for 30s. Intestinal lumen contents were collected from GF NOD mice or 
SPF NOD mice by flushing the small intestine, cecum and colon with 10 ml of sterile PBS. All 
the samples were centrifuged (300 g, 1 min, RT) to remove the large debris and further spun at 
12,000 g for 5 minutes to pellet bacteria. Supernatant was frozen at -20℃ for free IgA analysis. 
Bacterial pellets were washed and re-suspended in 50 µl of 1% BSA/PBS for 15 minutes at room 
temperature prior to the incubation with anti-IgA antibody for 30 minutes at room temperature. 
Samples were then washed and resuspended in sterile PBS, for analysis on a BD LSRII flow 
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cytometer, and further analyzed using Flowjo software. Bacteria from human stool were stained 
with anti-human IgA-PE antibody (Miltenyi). Bacteria from mice were stained with goat anti-
mouse IgA-PE (Southern Biotech), and isotype control antibodies (BioLegend). 
 
Oral gavage 
Fresh human stool samples were aliquoted immediately after collection. Bacterial pellets from 
fresh stool samples were re-suspended in sterile PBS and stored in 50% glycerol at -80°C. 
Before gavage, frozen bacteria were quickly thawed in 37°C water bath and then washed twice in 
sterile PBS. Bacterial colony forming units (CFU) were determined by measurement of optical 
density (OD) with a pre-titrated control bacterium E coli. 4-week-old GF NOD mice were 
colonized with 100 μl sterile PBS containing 2 × 108 CFU of stool bacteria from either 
individuals with T1D or controls. Colonized mice were terminated one week post-gavage. For 
the in vivo acetate experiments, 4-week-old GF NOD mice were colonized with 100 μl sterile 
PBS containing 2 × 108 CFU stool bacteria from individuals with T1D. One week post-
colonization, the mice were orally gavaged with 100mM sodium acetate in 200 μL of sterile 
water (H2O) every two days. These mice were terminated 2 weeks post-colonization (one-week 
post-acetate or water treatment). For SPF NOD mice, 4-week-old female mice were gavaged 
with 100mM sodium acetate in 200 μL of sterile water every two days over 10-12 weeks. 
Control mice in each experiment were gavaged with 200 μL of sterile water. 
 
Determination of bacterial product reactive IgA 
Fecal microbiota (1 x 109 CFU/ml) from 2 month-old Rag-/- NOD mice were alkaline lysed by re-
suspending in 0.1M NaHCO3 buffer (pH 9.1) and debris-free phase was used to coat the wells of 
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a 96-well ELISA plate (50 μl/well) overnight at 4°C. After washing, plates were blocked with 
1% BSA/PBS for 1 h at 37°C. Serum or gut flushes (non-bacteria-containing supernatants of 
small intestine, cecum, and large intestine) from SPF NOD females treated with water or acetate 
were assessed. Serum was diluted 1:100 in 1% BSA/PBS while gut flushes were used without 
further dilution. Samples (all in duplicate) were added to the appropriate wells and the plates 
were incubated at 37°C for 1.5 h. Samples were washed and then incubated with IgA-AP (1:1000 
dilution; Southern-Biotech) at 37°C for a further 1.5 h. Following the final wash, substrate PNPP 
was added. The reaction was stopped by adding 1N NaOH. Samples were then analyzed on a 
microplate spectrophotometer (Perkin Elmer) at 405 nm (OD). Antibody concentrations were 
determined by linear regression. 
 
Lamina propria (LP) immune cell isolation 
Mouse large intestine (LI) was harvested. Luminal contents were flushed with 10 ml sterile PBS. 
After removing Peyer's patches (PP), the intestine was cut longitudinally into 0.5 cm lengths and 
washed in phosphate-buffered saline (PBS). Gut tissue was then shaken for 20 min at 250 rpm at 
37°C in pre-warmed HBSS containing 1 mM EDTA. Tissue was vortexed at maximum speed for 
30 seconds. The solution was then filtered through nylon mesh. The remaining gut tissue was 
further digested with 1 mg/ml collagenase D and 500 U DNAse1 in RPMI medium and 
incubated for 1 h with rotation at 250 rpm, 37°C for LP lymphocyte isolation. Immune cells from 
LP were purified by Percoll (Sigma) gradient. 
 
Gut permeability assay 
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Mice were fasted overnight for 13 hours before the gavage with FITC-dextran (600 mg/kg) 
(Sigma). Baseline blood samples were collected from the mice prior to oral gavage with FITC-
dextran in sterile PBS. Two hours post-gavage, food supply was restored to the mice. Another 
two hours later, blood samples were collected from the mice. Blood was centrifuged (2300 g, 
5mins, room temp) to isolate serum. Serum samples were diluted 1:1 in PBS in a 96-well plate 
and serum FITC-dextran concentration was determined using a fluorescence spectrophotometer 
(Perkin Elmer). Serum samples from non-FITC-dextran gavaged NOD mice were used as 
baseline. Standard curves were generated using known concentrations of FITC-dextran diluted in 
control serum. Concentrations were determined using linear regression. 
 
B cell purification and cell culture  
Splenocytes were isolated from 14-16 week-old acetate- or water-gavaged female SPF NOD 
mice. Splenic B cells were purified following the MagniSortTM Mouse B cell enrichment kit 
(eBioscience) with a purity of 93-97% verified by flow cytometry. Purified B cells were 
stimulated with 20 μg/ml anti-CD40 mAb (FGK4.5, BioXcell) and 10 μg/ml LPS (Sigma) with 
10 mM acetate or sterile PBS (solvent for acetate) for 5 days. Cell culture supernatants were 
collected for secreted IgA and cytokine measurement at the end of the culture. 
 
Monoclonal antibody staining of cells for analysis by flow cytometry 
One million (1 × 106) cells from different mouse lymphoid tissues were incubated with an Fc 
blocker in PBS at room temperature for 20 min before cell surface staining. For intracellular 
cytokine staining, Cells were incubated at 37°C for 4 h in the presence of 50 ng/ml PMA (Sigma), 
500 ng/ml of ionomycin (Sigma) and 1 μl of Golgi plugTM (BD Bioscience) followed by 
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monoclonal antibodies to surface molecules and intracellular cytokine staining. Samples were 
analyzed on a BD LSRFortessa flow cytometer and results were analyzed by FlowJo 8.8.6 (Tree 
star). 
 
Histopathology and insulitis score 
Pancreata from 14-16-week old SPF NOD (orally gavaged with acetate or water) were fixed in 
10% buffered formalin and paraffin-embedded. Tissues were stained with H&E and insulitis was 
scored by light microscopy by an individual blinded to the study. The following insulitis grading 
was used: 0, no infiltration; I, < 25% infiltration; II, 25% to 50% infiltration; III, > 50 % 
infiltration. 143-164 islets were scored for insulitis in each group (N = 6-7 mice). 
 
Murine antibody ELISA 
Murine IgA levels were measured by direct ELISA (Southern Biotech) in the samples of serum, 
culture supernatants and luminal gut contents from colonized GF NOD mice and SPF NOD mice. 
Briefly, wells of a 96-well plate were coated with samples or standards. After washing and 
blocking (1 h, room temperature with 1% BSA in PBS), the plates were then incubated with AP-
conjugated goat anti-mouse IgA (2 h, room temperature). Samples were subsequently washed 
and substrate PNPP (Sigma) was added. The reaction was stopped by adding 1M NaOH. 
Samples were analyzed on a microplate spectrophotometer (Perkin Elmer) at 405nm (OD). 
Antibody concentrations were determined by linear regression. 
 
Cytokine ELISA 
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Murine IL-6 was measured using the Mouse IL-6 ELISA kit following the manufacturer’s 
instructions (BioLegend). 
 
Real time quantitative PCR (qPCR) 
RNA from purified B cells or small intestinal tissue was extracted using Trizol reagent and 
RNeasy mini plus kit (QIAGEN). After quantification, 1 μg RNA was used for cDNA synthesis 
using the iScript cDNA synthesis kit (Invitrogen). Samples were analyzed on an iCycler qPCR 
machine (Bio-rad). Gene expression was determined using the 2−ΔΔCt method and normalization 
with the housekeeping gene, GAPDH. Primers sequences are listed in Table S2. Each sample 
was assayed in duplicate and the experiments were repeated at least twice. 
 
Antibodies and reagents 
The fluorochrome-conjugated monoclonal antibodies (mAbs) used in this study include: Anti-
human-PE-IgA (Miltenyi, Cat# 130-093-128); Anti-mouse-PE-IgA (0.2 mg/ml, Southern 
Biotech, Cat# 116428); Anti-mouse-PE-Cy7-TCRβ (0.2 mg/ml, BioLegend, Cat# 109222); Anti-
mouse-PE-Foxp3 (0.2 mg/ml, eBioscience, Cat# 2001196); Anti-mouse-PE-IL-6 (0.2 mg/ml, 
BioLegend, Cat# 504504); Anti-mouse-PE-Cy7-CD8 (0.2mg/ml, BioLegend, Cat# 100722); 
Anti-mouse-APC-IgM (0.2 mg/ml, BioLegend, Cat# 406509); Anti-mouse-Alexa Fluor 147-GL-
7 (0.5 mg/ml, BioLegend, Cat# 144606); Anti-mouse-FITC-CD21 (0.5 mg/ml, BioLegend, Cat# 
123408); Anti-mouse-FITC-CD4 (0.5 mg/ml, BioLegend, Cat# 100406); Anti-mouse-FITC-
TNF-α (0.5 mg/ml, BioLegend, Cat# 506304); Anti-mouse-PerCpCy5.5-CD45 (0.2 mg/ml, 
BioLegend, Cat# 102132); Anti-mouse-PerCpCy5.5-CD25 (0.2 mg/ml, BioLegend, Cat# 
101912); Anti-mouse-PerCpCy5.5-IFN-γ (0.2 mg/ml, BioLegend, Cat# 101912); Anti-mouse-
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APC/Cy7-CD19 (0.2 mg/ml, BioLegend, Cat# 115530); Anti-mouse-APC/Cy7-CD4 (0.2 mg/ml, 
BioLegend, Cat# 100414); Anti-mouse-APC/Cy7-IgD (0.2mg/ml, BioLegend, Cat# 108406, 
RB6-8C5); Anti-mouse-Pacific Blue-CD23 (0.5 mg/ml, BioLegend, Cat# 101616), and anti-
mouse-Pacific Blue-CD4 (0.5 mg/ml, BioLegend, Cat# 100428). Bacterial DNA isolation and 
pyrosequencing reagents were purchased from Qiagen and Roche, respectively. 
 
Statistics 
Statistical analysis was performed using GraphPad Prism software Vs7 for Mac. Data are 
expressed as mean ± SEM or median (25th-75th percentile). Differences between groups were 
analyzed using a two-tailed Student's t-test, one-way ANOVA or two-way ANOVA. 
Correlations were analyzed using a two-tailed Pearson correlation coefficient test and/or linear 
regression. Statistical analysis of microbial β-diversity was conducted using an analysis of 
similarities (ANOSIM). Differences between microbial species were determined following 
analysis using multiple t-tests with Bonferroni correction. P value and statistical analysis for 
each experiment are reported in the figure legends. P < 0.05 was considered significant.  
 
Study approval 
The use of animals in this study was approved by the Institutional Animal Care and Use 
Committee at Yale University. For human studies, all participants or their guardians provided 
informed consent. The research was approved by the Ethics Committee of the Second Xiangya 
Hospital. 
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Figures and figure legends 
 
Figure 1. Stool SCFA production and bacteria-targeting IgA response in individuals with 
T1D compared to control subjects. (A) Experimental design of the study in patients with T1D 
and healthy control subjects. (B-G) Stool microbiota composition was investigated by 16S rRNA 
sequencing (n = 19/group). Changes in alpha diversity were assessed by Chao richness (B) and 
number of observed species (C). Altered relative microbial abundances of Ruminococcaceae (D), 
Coprococcus (E), Roseburia (F) and Megamonas (G) between donors with T1D and controls are 
shown. (H-I) Stool acetate (H), and butyrate (I) concentrations from individuals with T1D and 
control subjects (n = 19/group). (J) Correlation between stool acetate level and serum fasting C-
peptide concentration (n = 15). Data are presented as mean ± SEM and were analyzed by a two-
tailed Student's t-test (B-I). Data in (J) was analyzed using a two-tailed Pearson correlation 
coefficient test and linear regression. 
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Figure 2. IgA-bound bacteria and the correlations with different SCFAs in individuals with 
T1D and control subjects. (A) Representative flow cytometric profiles of IgA-bound bacteria. 
(B) Summary of IgA-bound bacteria percentage from donors with T1D and healthy controls (n = 
19/group). (C-E) Correlations between stool acetate (C), butyrate (D) or propionate (E) 
concentration and the level of IgA-bound bacteria (The overall elevation or intercepts between 
the two groups was compared. The black circles show that there were more patients in the upper 
left areas, i.e., with a higher percentage of IgA-bound bacteria but lower stool SCFAs, n = 14-16). 
(F-H) Correlations between stool acetate concentration and the relative abundances of 
Eubacterium (F) and Hathewayi (Firmicutes) (G), and between stool butyrate concentration and 
Enterococcaceae (Firmicutes) abundance (H) (n = 17/group). Data are presented as mean ± SEM 
and were assessed for statistical significance using a two-tailed Student's t-test (B). Data in (F-H) 
were analyzed using a two-tailed Pearson correlation coefficient test and/or linear regression.  
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Figure 3. Role of gut microbiota from patients with T1D and control subjects in 
modulating host immune responses in germ-free (GF) NOD mice. (A) Timeline for GF NOD 
mice gavaged with stool bacteria from patients with T1D or control subjects. (B) Unweighted 
PCoA (Principal Coordinate Analysis) of stool microbiota from GF NOD mice received bacteria 
from either T1D donors or healthy control subjects (n = 22-23). (C) Gut microbiota composition 
at the species level (n = 22-23). (D) Gut permeability (n = 9-15). (E) Expression of Cramp (n = 
16/group). (F) IgA+ B cell frequency in the spleen, PLN, MLN and PP (n = 27-30). (G-H) 
Representative flow cytometric profiles of IgA-bound bacteria (G), and summary of IgA-bound 
bacteria percentage (H). Statistical analysis was performed by an analysis of similarities 
(ANOSIM) (B), multiple t-tests with Bonferroni correction (C), or a two-tailed Student's t-test 
(D-F and H, data combined from two or more independent experiments are presented as mean ± 
SEM). PLN, pancreatic lymph node; MLN, mesenteric lymph node; PP, Peyer’s patch. 
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Figure 4. Role of acetate in modulating gut microbiota composition and IgA immune 
response. (A) Spleen cells from specific pathogen-free (SPF) NOD mice were stimulated with 
acetate, butyrate, or propionate (all 0.1mM) in the presence of anti-CD40 mAb (20 μg/ml) and 
LPS (10 μg/ml), and secreted IgA in the culture supernatant was measured (n = 8/group). (B) 
Timeline of GF NOD mice gavaged with stool bacteria from patients with T1D, followed by 
acetate or water gavage. (C-E) Gut microbiota in fecal samples were analyzed by 16S rRNA 
sequencing (n = 7-8). Chao richness (C), relative abundance of Porphyromonadaceae (D) and 
Staphylococcaceae (E) at family level. (F) Proportion of TCRbeta+CD4+ T cells, TCRbeta+CD8+ 
T cells and TCRbeta-CD19+ B cells in PP (n = 7-8). (G) Frequency of CD4+CD25+Foxp3+ Treg 
cells in PP (n = 7-8). (H) Proportion of IgA+ B cells in PLN (n = 6-8). (I) Proportion of IgA+, 
IgM+ and IgD+ B cells in bone marrow (BM) (n = 7-8). (J) IgA concentration from the content of 
small intestine, cecum and colon (n = 7-8). Data combined from two independent experiments 
are presented as mean ± SEM and were analyzed with a one-way ANOVA followed by a Tukey 
test with Dunn’s correction for subsequent multiple comparisons between two groups (A) or a 
two-tailed Student's t-test (C-J). PLN, pancreatic lymph node. 
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Figure 5. Long-term effect of acetate treatment on IgA response in specific pathogen-free 
(SPF) NOD mice. (A) Timeline of SPF NOD mice gavaged with acetate or water. (B) 
Longitudinal proportion of IgA-bound stool bacteria before and after gavage (n = 8-9). (C) Gut 
permeability (n = 7-9). (D) IgA concentrations in intestinal flush (n = 6-7). (E) Percentage of 
IgA-bound bacteria in the intestinal flush (n = 8-9). (F) Intestinal Pigr expression post-acetate 
treatment (n = 14-16). (G) IgA reactive to gut bacterial products. Stool microbiota from Rag-
deficient mice (without any type/form of antibodies) were used to assess IgAs reacting to gut 
bacterial products. IgAs reacting to the bacterial products in small intestinal flush from the mice 
with or without acetate treatment were determined by anti-mouse IgA by ELISA (n = 14-16). (H) 
Proportion of CD4+ or CD8+ T cells and CD19+ B cells in PP (n = 6-7). (I) Proportion of splenic 
IgA+ B cells (n = 6-7). Data were pooled from two or more independent experiments, and 
analyzed using either a Two-way ANOVA (B), or a two-tailed Student's t-test (C-I, Data are 
presented as mean ± SEM). 
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Figure 6. Long-term effect of acetate treatment on IgA response and insulitis in specific 
pathogen-free (SPF) NOD mice. (A) Proportion of PNA+GL-7+ germinal center B cells (n = 6-
7). (B) Percentage of splenic IgA+ GC B cells (n = 6-7). (C) Proportion of IgA+, IgD+ and IgM+ 
B cells in bone marrow (BM) (n = 8-9). (D) Representative insulitis images of microscopic views 
(×200) showing differences in immune cell infiltration marked by the black arrows. (E) 
Summarized percentage of severity of insulitis (total of 143-164 islets were graded from 6-7 
mice/group). (F) Infiltrated immune cells in the islets (n = 6-7). Data were pooled from two or 
more independent experiments, and analyzed using either a two-tailed Student's t-test (A-C, and 
F, Data are presented as mean ± SEM) or a Chi square test (E). PLN, pancreatic lymph node; 
MLN, mesenteric lymph node; PP, Peyer’s patch.  
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Figure 7. Direct effect of acetate on B cells. Ex vivo splenic B cells were purified from specific 
pathogen-free (SPF) NOD mice gavaged with acetate or water for 10-12 weeks. The purified B 
cells were stimulated in vitro in the presence of 10 mM acetate with 20 μg/ml anti-CD40 mAb 
and 10 μg/ml LPS for 5 days. (A) IgA concentration in the culture supernatant of stimulated B 
cells was measured by ELISA (n = 8-9). (B) Representative flow cytometric plots of intracellular 
IL-6 expression of B cells after acetate stimulation. (C) Summary of IL-6-expressing B cells. (D) 
Secreted IL-6, determined by ELISA, from the culture supernatant of B cells stimulated with 
acetate (n = 6-7). (E-H) Gene expression of B cells, after acetate stimulation, was assessed by 
qPCR –Pstα (E), Pst2β (F), Stat5b (G), and Irf4 (H). The expression levels were determined 
using the 2−ΔΔCt method by normalizing the housekeeping gene Gapdh. Data combined from two 
independent experiments are presented as mean ± SEM and were analyzed using a two-tailed 
Student's t-test (A, C-H). 
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Figure 8. Gene expression of gprs and solute carrier family 16 on B cells. Ex vivo splenic B 
cells were purified from specific pathogen-free (SPF) NOD mice gavaged with 200 μL of water 
or equivalent volume of 100 mM acetate for 10-12 weeks, and were stimulated in vitro with 20 
μg/ml anti-CD40 mAb and 10 μg/ml LPS in the presence of 10 mM acetate for 5 days. (A-E) 
Gene expression of acetate-stimulated B cells was assessed by qPCR: Gpr41 (A), Gpr43 (B), 
Slc16a7 (C), Slc16a1 (D) and Slc16a3 (E). All expression data were determined using the 
2−ΔΔCt method by normalization with the housekeeping gene GAPDH. Data combined from two 
independent experiments are presented as mean ± SEM and were assessed for statistical 
significance using a two-tailed Student's t-test (n = 7-8). 
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Tables 
Table 1. Characteristics of patients with newly diagnosed type 1 diabetes and age- and 
gender-matched control individuals. 
 Type 1 diabetes Healthy controls 
N (Females/males) 19 (12/7) 19 (12/7) 
Age (years) 9.2 (8.0-12.0) 10.3 (6.5-11.5) 
Fasting glucose (mmol/L) 6.7 (5.2 -9.3)A 4.8 (4.3 – 5.1) 
HbA1c (%) 9.3 ± 2.8 N/A 
Fasting C-peptide (pmol/L) 94.0 (34.0-137.3) N/A 
1h postprandial C-peptide (pmol/L) 156.7 (53.5-299.1) N/A 
2h postprandial C-peptide (pmol/L) 218.9 (83.6-329.9) N/A 
T1A/T1B 15/4 N/A 
 
Data are presented as mean ± SEM or median (25th-75th percentile) as appropriate; N/A, not 
available. A: P < 0.001. Data were assessed for significance using a two-tailed Student's t-test. 
